新型治疗策略改变了儿童克罗恩病的自然史:一项为期二十年的基于人群的研究
该研究基于EPIMAD登记库,纳入1988至2011年诊断的1007例儿童期起病克罗恩病患者,回顾性随访至2013年,比较三个诊断时期(前免疫抑制剂时代、前抗TNF时代、抗TNF时代)的用药暴露与疾病结局。结果显示,随免疫抑制剂和抗TNF使用增加,5年肠道切除风险和狭窄并发症风险显著下降,而 flare 相关住院风险保持稳定。
要点
- 5年免疫抑制剂暴露率从33.9%(P1)升至76.5%(P3),抗TNF从0%(P1)升至50.5%(P3)。
- 5年肠道切除风险从35%(P1)降至22%(P3),前抗TNF时代32% vs 抗TNF时代22%(P=0.0007)。
- 5年狭窄进展风险从28%(前抗TNF时代)降至20%(抗TNF时代)(P=0.040)。
核心结论
- 随着免疫抑制剂和抗TNF使用增加,在人群水平观察到儿童期起病克罗恩病自然史的积极变化,抗TNF时代肠道切除和狭窄并发症风险降低。
研究设计与样本
- 基于EPIMAD登记库的回顾性队列研究,纳入1988至2011年诊断的1007例17岁以下克罗恩病患者,随访至2013年。
- 定义三个诊断时期:1988-1993年(P1,前免疫抑制剂时代)、1994-2000年(P2,前抗TNF时代)、2001-2011年(P3,抗TNF时代)。
- 中位随访8.8年(四分位距4.6-14.2年)。
主要发现
- 5年免疫抑制剂暴露率从33.9%(P1)升至76.5%(P3),5年抗TNF暴露率从0%(P1)升至50.5%(P3)。
- 5年肠道切除风险:P1为35%、P2为31%、P3为22%(P=0.0003,趋势P<0.0001);前抗TNF时代(P1+P2)为32% vs 抗TNF时代(P3)为22%(P=0.0007)。
- 5年从炎症型进展为狭窄型的风险:P1为27%、P2为28%、P3为20%(P=0.11,趋势P=0.041);前抗TNF时代(P1+P2)为28% vs 抗TNF时代(P3)为20%(P=0.040)。
- 5年克罗恩病 flare 相关住院风险:P1为31%、P2为31%、P3为29%(P=0.76,趋势P=0.53)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We evaluated the impact of immunosuppressants (IS) and anti-tumor necrosis factor (TNF) introduction on Crohn's disease (CD) long-term outcomes in a large population-based, pediatric-onset cohort. METHODS: All patients included in the EPIMAD registry with a diagnosis of CD occurring when they were younger than age 17 years and between 1988 and 2011 were followed up retrospectively until 2013. Three diagnostic periods were defined: 1988 to 1993 (period [P]1; pre-IS era), 1994 to 2000 (P2; pre-anti-TNF era), and 2001 to 2011 (P3; anti-TNF era). Medication exposure and disease outcomes were compared between the 3 diagnostic periods. RESULTS: A total of 1007 patients diagnosed with CD were followed up for a median duration of 8.8 years (interquartile range, 4.6-14.2 y). The IS and anti-TNF exposure rate at 5 years increased over time from 33.9% (in P1) to 76.5% (in P3) and from 0% (in P1) to 50.5% (in P3), respectively. In parallel, the risk for intestinal resection at 5 years decreased significantly over time (P1, 35%; P2, 31%; and P3, 22%; P = .0003, Ptrend < .0001), and between the pre-anti-TNF era (P1 + P2, 32%) and the anti-TNF era (P3, 22%) (P = .0007). The risk for progression from inflammatory to stricturing behavior decreased significantly over time (P1, 27%; P2, 28%; and P3, 20%; P = .11, Ptrend = .041) and between the pre-anti-TNF era (P1 + P2, 28%) and the anti-TNF era (P3, 20%) (P = .040). The risk for a CD flare-related hospitalization at 5 years remained stable over time (P1, 31%; P2, 31%; and P3, 29%; P = .76, Ptrend = .53). CONCLUSIONS: In parallel with the increased use of IS and anti-TNF, positive changes in the natural history of pediatric-onset CD were observed at the population level. A decreased risk of both intestinal resections and stricturing complications were observed during the anti-TNF era.
引用
- Ley D, Leroyer A, Dupont C, et al. New Therapeutic Strategies Have Changed the Natural History of Pediatric Crohn's Disease: A Two-Decade Population-Based Study. Clin Gastroenterol Hepatol. 2022. PMID: 35131345. doi:10.1016/j.cgh.2022.01.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。